Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on August 21, 2024 that the Company… Read More »Asarina Pharma applies for the delisting of the company’s shares
Asarina Pharma AB (publ) held on 21 August 2024 an extraordinary general meeting, and first control meeting, at which the shareholders resolved that the company… Read More »Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma
The shareholders of Asarina Pharma AB (publ), reg. no. 556698-0750, (the “Company”) are hereby given notice to attend the extraordinary general meeting and first control… Read More »NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)
Asarina Pharma AB (publ) ("Asarina Pharma” or the ”Company”) today announces that the Company is discontinuing its efforts to find a partner for the future… Read More »ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (the “Company”) on 27 June 2024 at Fredersen… Read More »Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
(Stockholm, 4 June 2024) Asarina Pharma (“the Company”) today announces the release of its 2023 Annual Report. Status and OutlookSince completing the phase IIa study… Read More »ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to June… Read More »Asarina Pharma AB announces new date for the release of Annual Report for 2023
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to 28… Read More »Asarina Pharma AB announces new date for the release of Annual Report for 2023
(Stockholm, 27 February 2024) Asarina Pharma (“the Company”) today releases its Second Half-Year and Year-End Report for 2023. The full Report (in English) is available… Read More »ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023
Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB. The Company has entered into… Read More »Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB